Lundbeck Looks For Assets Across Value Chain To Ride Storm
While the Danish pharma unveiled its best ever financial results, recently installed ceo Deborah Dunsire confirms to Scrip that the company needs to bolster its pipeline and portfolio with assets in all phases of the value chain.
You may also be interested in...
Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.